Drug Interactions: Avoid concurrent use with strong or moderate CYP3A inhibitors or inducers.
Proton Pump Inhibitors: Consider using short-acting antacids or H2 blockers instead of PPIs. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours.
Substrates of P-glycoprotein: BOSULIF may increase the plasma concentrations of drugs that are P-gp substrates, such as digoxin.
Nursing Mothers: Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or BOSULIF.Hepatic Impairment: Treat with a dose of 200 mg daily in patients with any baseline hepatic impairment. For more information and full prescribing information, please visit www.BOSULIF.com. About Pfizer Oncology Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Hematologic cancers are a complex group of diseases, with over 70 different types of lymphomas, leukemias or myelomas. While there have been significant advancements in the treatment of some hematologic cancers, there continues to be a need for additional therapeutic options. Pfizer Oncology is committed to improving outcomes for patients living with hematologic malignancies like CML. Pfizer Oncology has a robust hematology pipeline, with biologics and small molecules in clinical development across a number of hematologic malignancies. We are advancing technologies as well as working to identify new and innovative options that address specific hematologic cancers, molecular subtypes, gene over-expression and mechanisms of resistance. For more information, please visit www.Pfizer.com. DISCLOSURE NOTICE: The information contained in this release is as of November 29, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s hematology pipeline in general and about BOSULIF (bosutinib) and inotuzumab ozogamicin, including their potential benefits, in particular, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for BOSULIF (bosutinib) or inotuzumab ozogamicin as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of BOSULIF (bosutinib) or inotuzumab ozogamicin; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K. 1 ASH Accepted Abstract #69 Assessment of Early Molecular Response as a Predictor of Long-term Clinical Outcomes in the Phase 3 BELA Study. Oral Presentation, December 9, 2012: 12:30am ET. T. Brummendorf – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 2 ASH Accepted Abstract # 2793. Baseline Predictors of Response to Bosutinib in Patients With Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib (Study 200).General Poster Session, December 9, 2012: 6:00 – 8:00 pm ET. J. Cortes – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 3 ASH Accepted Abstract #2798. Assessment of Early Cytogenetic Response as a Predictor of Long-term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML (Study 200).General Poster Session, December 9, 2012: 6:00 – 8:00 pm ET. J. Cortes – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 4 ASH Accepted Abstract #3779. Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-month Minimum Follow-up Update (Study 200) General Poster Session, December 10, 2012: 6:00 – 8:00 pm ET. J. Cortes – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 5 ASH Accepted Abstract #3785. Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/or Nilotinib: 24-month Minimum Follow-up Update (Study 200) General Poster Session, December 10, 2012: 6:00 – 8:00 pm ET. H. Jean Khoury – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 6 ASH Accepted Abstract #1633. An Open-label, Phase 1 Study of R-CVP in Combination with InotuzumabOzogamicin in Patients with CD22-positive B-cell Non-Hodgkin’s Lymphoma: Preliminary Safety and Efficacy Data. General Poster Session, December 8, 2012: 5:30 – 7:30 pm ET. M. Ogura – Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 7 ASH Accepted Abstract #2612. Weekly InotuzumabOzogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia. General Poster Session, December 9, 2012: 6:00 – 8:00 pm ET. D. DeAngelo– Presenter. 54th American Society of Hematology Annual Meeting. Atlanta, GA. December 8-11, 2012. 8 Clinicaltrials.gov. A Study of InotuzumabOzogamicinPlus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who are Not Candidates for Intensive High-Dose Chemotherapy. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01232556?term=inotuzumab+ozogamicin&phase=2&rank=2. Accessed November 3, 2011. 9 Clinicaltrials.gov. A Study of InotuzumabOzogamicin versus Investigator’s Choice of Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. Available here: http://www.clinicaltrials.gov/ct2/show/NCT01564784?term=inotuzumab&rank=7. Accessed April 12, 2012. 10 Boni J et al. Modeling the Pharmacokinetic/Pharmacodynamic Platelet Response of InotuzumabOzogamicin, a Novel Antibody Drug Conjugate, Administered Alone or in Combination with Rituximab in Patients with Non-Hodgkin’s Lymphoma. Accepted Poster Presentation at the European Society of Medical Oncology 2010 Annual Meeting, October 8-12, 2010. Milan, Italy. 11 Leonard J et al. Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma: a Phase I/II Clinical Trial Results. Clinical Cancer Research.2004; 10: 5327-5334. 12 DiJoseph J et al. Antibody-Targeted Chemotherapy with CMC-544: a CD22-Targeted Immunoconjugate of Calicheamicin for the Treatment of B-Lymphoid Malignancies. Blood. 2004; 1-3: 1807- 1814. 13 American Cancer Society.Non-Hodgkin Lymphoma. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003126-pdf.pdf. Accessed April 25, 2011. 14 Francisco Blood 2003; ADC Message Landscape slide 17, point 3.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV